Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumabAlexander M. Menzies, Georgina V. Long, Oliver Klein et al.|Annals of Oncology|2016Cited by 822
Clinical outcomes in metastatic uveal melanoma treated with PD‐1 and PD‐L1 antibodiesAlain P. Algazi, Ryan J. Sullivan, Katy K. Tsai et al.|Cancer|2016Cited by 375
A randomised phase II trial of selumetinib vs selumetinib plus temsirolimus for soft-tissue sarcomasZeynep Eroglu, Warren Chow|British Journal of Cancer|2015Cited by 37
A phase II, randomized study of nivolumab (NIVO) and Ipilimumab (IPI) versus NIVO, IPI and stereotactic body radiation therapy (SBRT) for metastatic Merkel cell carcinoma (MCC, NCT03071406): A preliminary reportS. Kim, Andrew S. Brohl, Nikhil I. Khushalani et al.|Annals of Oncology|2019Cited by 5
LBA42 Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinomaS. Kim, Andrew S. Brohl, Evan Wuthrick et al.|Annals of Oncology|2022Cited by 0